DS
CARM

DRW Securities’s Carisma Therapeutics CARM Stock Holding History

DRW Securities’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-17,335
Closed -$492K – 82
2018
Q4 		$492K Buy
17,335
+4,830
+39% +$154K 0.03% 41
2018
Q3 		$538K Buy
12,505
+5,005
+67% +$195K 0.03% 26
2018
Q2 		$293K Buy
7,500
+5,500
+275% +$242K 0.02% 50
2018
Q1 		$42K Buy
+2,000
New +$38.4K ﹤0.01% 161

Other funds holding CARM

KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CHP
Castle Hook Partners New York $23.4B AUM 158.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DRW Securities's CARM Position: Q1 2019 in Review

DRW Securities sold out of Carisma Therapeutics (CARM) in Q1 2019, closing a stake of 17,335 shares — an estimated $492K sold.

DRW Securities first reported a position in CARM in Q1 2018 and held it in 4 quarters. The position peaked at $538K in Q3 2018. 48 funds tracked by Wall St. Rank hold CARM as of Q1 2019.

  • DRW Securities reported no remaining Carisma Therapeutics position as of Q1 2019 after selling out during the quarter.
  • DRW Securities sold 17,335 Carisma Therapeutics shares in Q1 2019, an estimated $492K.
  • DRW Securities first reported a position in Carisma Therapeutics in Q1 2018 and held it in 4 quarters.
  • DRW Securities's Carisma Therapeutics position peaked at $538K in Q3 2018.
  • 48 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2019.

Based on DRW Securities's 13F filing for Q1 2019, filed 15 May 2019.